Adverum Biotechnologies: Gene Therapy Company And Our New … – Seeking Alpha
Seeking Alpha |
Adverum Biotechnologies: Gene Therapy Company And Our New …
Seeking Alpha The stock is at an attractive entry point ahead of phase I/II data from a gene therapy trial in alpha-1 antitrypsin deficiency in the second half of this year. We are rating the stock a Buy with price target = $18. We bought shares of Adverum … Adverum Biotechnologies, Inc. (ADVM) Declined to $5.45 on Apr, 8 What's Adverum Biotechnologies, Inc. (ADVM) Downside After Today's Significant Decline? Zacks Premium Investment Service – Zacks.com |
